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Background: Left ventricular dysfunction (LVD) with subsequent congestive heart failure
(CHF) constitutes the final common pathway for a host of cardiac disorders. The impaired
LV function develops in response to an ischemic insult followed by a fall in cardiac output
that leads to activation of renin-angiotensin-system (RAS). Angiotensin II type I receptor
(AT1), which mediate the vasoconstrictive and salt-conserving actions of the RAS, repre-
sent interesting candidate genes for cardiovascular diseases. Therefore, we conducted an
association study between single nucleotide polymorphism (SNP) in AT1 gene and LVD in
CAD patients.
Methods and results: The present study recruited a total of 950 subjects including 720
angiography confirmed CAD patients and 230 healthy controls. Among 720 CAD patients,
229 with reduced left ventricle ejection fraction (LVEF 45%) were categorized as LVD. The
AT1 (A1166C, rs5186) polymorphism was determined by ARMS-PCR. Our results showed
that the frequency of AT1 1166AC and CC genotypes were significantly higher in LVD pa-
tients in comparison to non-LVD (LVEF >45%) patients (p value ¼ 0.003; OR ¼ 1.81 and p
value <0.001; OR ¼ 4.33). Further analysis showed that AT1 A1166C polymorphism was
significantly associated with LV end diastole (p-value ¼ 0.031), end systole (p-value ¼ 0.038)
dimensions, and mean LVEF (p-value ¼ 0.035). Moreover, on comparing the AT1 A1166C
polymorphism in CAD patients with healthy controls, we did not find any association both
at genotypic and allelic level (p value ¼ 0.927; OR ¼ 1.04 and p value ¼ 0.219; OR ¼ 0.83)
respectively.2.
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conferring genetic susceptibility of LVD.
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Left ventricular dysfunction (LVD) with subsequent conges-
tive heart failure (CHF) constitutes the final common pathway
for a host of cardiac disorders. Coronary artery narrowing or
ischemic heart disease is the dominant cause of LVD and is
often associated with acute or prior myocardial infarction.1
Left ventricular remodeling is a key process, determining
disease progression and affecting outcome in this condition.
This is further characterized by the continuous interactions
between the underlyingmyocardial dysfunction and activated
compensatory neurohumoral mechanisms.2 Being a progres-
sively debilitating condition and despite broad array of treat-
ment, a significant heterogeneity exists in the benefits to
individual subject and genetic differences may provide an
explanation for the fact that some people, irrespective of
lifestyle and common classical cardiovascular risk factors, are
more prone to develop LVD.
New molecular biology techniques applied to genetic
diagnosis make it possible to study the mechanisms under-
lying individual and familial predisposition to suffering
certain diseases. Specifically, in relation to coronary artery
disease, the genetic markers linked to the renin-angiotensin-
system (RAS) have received special attention, not only
because of their well-known effects on vascular homeostasis3
but also the promise of the use of angiotensin-converting
enzyme inhibitor (ACEI) and angiotensin receptor blockers
(ARBs) to reduce morbidity and mortality in ischemic heart
disease.4
Angiotensin II (Ang II) is an active component of the RAS
and the majority of the known action of Ang II relevant to
cardiovascular function and structure are mediated by
angiotensin II type1 (AT1) receptor. AT1 receptor, located in
vascular smooth muscle cells and myocardium, mediates the
vasoconstrictive and salt-conserving actions of the RAS, and
therefore represents interesting candidate gene for cardio-
vascular diseases. A single nucleotide polymorphism (SNP),
A1166C, located in the 30 untranslated region (UTR) of AT1
gene, has been characterized and investigated in relation to
arterial hypertension,5 hypertension-induced hypertrophy,6
aortic stiffness,7 myocardial infarction,8 and carotid intimal-
medial thickening.9 AT1 A1166C polymorphism has been
associated with essential hypertension,10,11 aortic stiffness,7
collagen type I synthesis, and myocardial stiffness in pa-
tients with hypertensive heart disease12 and cardiac
hypertrophy.13
In our previous study we showed that in RAS, AT1 A1166C
polymorphism was associated with LVD in a small subset of
CAD patients.14 However, the aim of the present study was to
assess whether AT1 A1166C polymorphism associated with
LV ejection fraction (LVEF) and other echocardiography pa-
rameters such as LV end diastole dimension (LVEDD), LV endsystolic dimension (LVESD), and LV mass in a larger sample
size. In addition, we have done an extensive statistical
analysis with different variables to explore a more clear
picture of AT1 A1166C (rs5186) polymorphism in the devel-
opment of LVD.2. Materials and methods
2.1. Study population
The present study recruited a total of 950 subjects including
720 CAD patients and 230 healthy controls. All the patients
had significant coronary artery disease (diagnosis, confirmed
by coronary angiography and further all these subjects un-
derwent either coronary angioplasty or Coronary Artery
Bypass Graft (CABG) surgery), recruited from the Department
of Cardiology and Department of Cardiovascular and Thoracic
Surgery (CVTS) of Sanjay Gandhi Postgraduate Institute of
Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India.
The detailed clinical history of CAD patients was based on
hospital investigations including coronary angiography. An-
giographically identified stenosis >70% in the major coronary
vessels at the time of the study were used to classify patients
as having single-vessel, double-vessel, or triple-vessel dis-
ease. The control population consisted of 230 subjects (191
males and 39 females) (mean age years 54.18 ± 8.47) with no
clinical evidence of CAD or LV dysfunction (by echocardiog-
raphy) and also without positive family history of CAD or
myocardial infarction (MI). Furthermore, the inclusion criteria
for controls were absence of prior history of high systolic
blood pressure, abnormal lipid profile, hypertension and
obesity. Both patients and controls were frequency-matched
to age, gender and ethnicity. To test the possibility for popu-
lation stratification, genomic control method was used as
described by Devlin et al.15 After obtaining informed consent,
all the individuals were personally interviewed for informa-
tion on food habits, occupation and tobacco usage. The study
was approved by local ethical review committees of the
institute (IEC CodeNo: A-01:PGI/SRF/IEC/54/29.04.2011)and the
authors followed the norms of World's Association Declara-
tion of Helsinki.162.2. Data collection
The clinical data was obtained by reviewing the patient's
medical records. Left ventricle ejection fraction (LVEF) was
calculated quantitatively by echocardiography, just before
angiography procedure, using the Simpson's method.17 LV
mass was calculated by using the following formula: 0.8 [1.04
{(LV diastolic internal dimension þ inter-ventricular
septum þ posterior wall)3(LV diastolic internal dimension)
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 1 4e2 2 12163}]þ0.6.18 Echocardiography was repeated in 10% of patients
and results were totally concordant. Hypertension was
defined as systolic blood pressure >140 mmHg or a diastolic
blood pressure >90 mmHg or patients using antihypertensive
drugs. Smoking was classified as smokers (ex-smoker and
current smokers) and non-smokers. Similarly, diabetes mel-
litus was defined as patients with fasting plasma glucose
>6.9 mmol/L or patients using anti-diabetic medication. All
laboratory parameters, as stated in the medical record, were
determined in overnight-fasting patients.2.3. Genotyping
Genomic DNA was isolated from peripheral blood leukocytes
according to a standard salting out method.19 AT1 A1166C
polymorphism was genotyped using ARMS-PCR method. As a
negative control, PCR mix without DNA sample was used to
ensure contamination free PCR product. Genomic DNA was
amplified in a DNA thermal cycler (Eppendorf Germany) using
a set of outer (Forward outer (GCCAAATCCCACT-
CAAACCTTTCAACAA)/Reverse outer AAGCAGGCTAGGGA-
GATTGCATTTCTGT) and a set of inner [Forward inner (A
allele) TCTGCAGCACTTCACTACCAAATGAACA/Reverse inner
(C allele) TCTCCTTCAATTCTGAAAAGTAGCTGAG] primers
described by Shu Ye et al.20 PCR was conducted in a total
volume of 25 ml with 2 pmol of outer primers and 16 pmol of
inner primers, genomic DNA (100e150 ng), 10 mM dNTPs, PCR
buffer containing final concentrations of 50 mM KCl; 10 mM
TriseHCl (pH 8.3); 1.5 mM MgCl2 and 1.5 units of Taq DNA
polymerase (Bangalore Genei, India).
2.3.1. PCR conditions
Initial denaturation: 95 C for 2 min; Denaturation, 95 C for
1 min; Annealing, 58 C for 1 min; Extension, 72 C for 1 min
and Final extension at 72 C for 2min. The PCRwas carried out
for 35 cycles.
The PCR fragments were separated on 2% agarose gel,
stained with ethidium bromide and observed with ultraviolet
imaging system (Bio-Rad Gel DocTM EZ Imager, USA). Repre-
sentative gel picture is given in Fig. 1. Genotyping was per-
formed without knowledge of the case or control status. TenFig. 1 e Representative gel picture of AT1 A1166C
polymorphism: Lane 1, CC genotype; Lane 2, AC genotype;
Lane 3, 100 bp DNA ladder; Lane 4, AA genotype.percent of samples for each genotype were sequenced which
showed 100% concordance.
2.4. Statistical analysis
The sample size was calculated using QUANTO 1.1, using
minor allele frequency data from HapMap (http://www.
hapmap.org/). The sample size of both 720 patients and 230
controls were adequate to give us power of 80% (probability of
not making a type II error). Descriptive statistics were pre-
sented as mean and standard deviation (SD) for continuous
measures while absolute value and percentages were used for
categorical measures. The chi-square goodness of fit test was
used for any deviation from Hardy Weinberg Equilibrium in
controls. Differences in genotype and allele frequencies be-
tween study groups were estimated by chi-square test. The
ORs were adjusted for confounding factors such as age and
gender. In addition, the association between AT1 A1166C gene
polymorphism and significant risk factors of CAD was
analyzed by using binary logistic regression. A two-tailed p-
value of less than 0.05 was considered as statistical significant
result. All statistical analyses were performed using SPSS
software version 16.0 (SPSS, Chicago, IL, USA).3. Results
3.1. Patient characteristics
Of the total 720 CAD patients, 68.2% showed preserved (>45%)
ejection fraction (Non-LVD) while 31.8% had reduced (45%)
ejection fractions (LVD), according to criteria used previ-
ously.14,21 A comparison of demographic profile and clinical
characteristics between LVD and Non-LVD patients is shown
in Table 1. The mean age (56.20 ± 8.47 v/s 55.54 ± 9.54) and
male/female ratio (89.1% v/s 86.4%) were not significantly
different between the LVD and Non-LVD patients. Hyperten-
sion and diabetes are common in CAD patients, but their
incidencewas not significantly different among LVD andNon-
LVD patients. Lipid levels and bodymass index (BMI) were also
comparable between the two groups. However, a higher per-
centage of LVD patients were smokers as compared to Non-
LVD patients (31.4% v/s 21.6%, p ¼ 0.005). The frequency of
STEMI (ST-elevation myocardial infarction), a well known
predictor of LVD, was also significantly different between the
LVD and Non-LVD patients (69.9% v/s 37.5%, p < 0.001). The
angiographic profile categorized patients with single vessel
disease (SVD), double vessel disease (DVD), and triple vessel
disease (TVD) as 60.1%, 17.4% and 22.5% respectively in CAD
patients. Among all CAD patients, complete revascularization
was done in 82.8% patients. There was no significant differ-
ence in the frequency of SVD, DVD, and TVD between the two
groups. The percentage of complete revascularization was
also comparable between these two groups. Among echocar-
diography traits, LV ejection fraction (p < 0.001), LV end dias-
tole dimension (p < 0.001), LV end systolic dimension
(p < 0.001), Posterior wall end diastole dimension (p ¼ 0.027)
and LV mass (p ¼ 0.014) were significantly different between
LVD and Non-LVD groups which clearly demarked these two
different populations (Table 1).
Table 1 e Demographic profile and clinical characteristics of CAD patients with LVD v/s Non-LVD.
Clinical characteristics CAD LVD (LVEF  45%) Non-LVD (LVEF > 45%) p-values
Total subjects 720 229 491 e
*Age e yr 55.79 ± 9.22 56.20 ± 8.47 55.54 ± 9.54 0.372
Male sex 628 (87.2%) 204 (89.1%) 424 (86.4%) 0.339
Risk factors
Hypertensive 317 (44.0%) 96 (41.9%) 221 (45.0%) 0.468
Diabetic 230 (31.9%) 82 (35.8%) 148 (30.1%) 0.145
Smokers 178 (24.7%) 72 (31.4%) 106 (21.6%) 0.005
*BMI 24.27 ± 3.06 24.51 ± 3.23 23.84 ± 2.68 0.120
*Lipid profiles (mg/dl)
High density lipoprotein, HDL 32.19 ± 7.92 31.05 ± 6.75 32.66 ± 8.34 0.385
Low density lipoprotein, LDL 74.31 ± 26.24 73.98 ± 24.82 74.46 ± 26.95 0.909
Triglycerides (TG) 146.30 ± 64.01 146.34 ± 63.68 146.27 ± 64.41 0.994
Total cholesterol (TC) 138.21 ± 38.66 138.40 ± 37.53 138.12 ± 39.30 0.963
Clinical syndrome
Stable angina 237 (32.9%) 36 (15.7%) 201 (40.9%) e
Unstable angina/NSTEMI 139 (19.3%) 33 (14.4%) 106 (21.6%) e
STEMI 344 (47.8%) 160 (69.9%) 184 (37.5%) <0.001
AWMI 187 (26.0%) 109 (47.6%) 78 (15.9%) e
IWMI 157 (21.8%) 51 (22.3%) 106 (21.6%) e
Angiographic profiles
Single vessel disease (SVD) 433 (60.1%) 134 (58.5%) 299 (60.9%) e
Double vessel disease (DVD) 125 (17.4%) 39 (17.0%) 86 (17.5%) e
Triple vessel disease (TVD) 162 (22.5%) 56 (24.5%) 106 (21.6%) 0.691
Complete Revascularization 596 (82.8%) 185 (80.8%) 411 (83.7%) 0.342
*Echocardiographic traits
LVEF, % 49.97 ± 11.18 35.94 ± 7.05 56.51 ± 5.05 <0.001
LVEDD, mm 47.21 ± 8.11 49.07 ± 6.99 44.48 ± 4.58 <0.001
LVESD, mm 31.05 ± 9.31 34.42 ± 7.69 28.93 ± 4.87 <0.001
Posterior wall end diastole dimension, mm 9.98 ± 1.87 9.59 ± 1.42 10.07 ± 1.49 0.027
Inter-ventricular septum end diastole dimension, mm 10.01 ± 1.98 9.91 ± 1.45 10.38 ± 1.76 0.051
LV mass (LV mass), gm 161.31 ± 55.56 175.39 ± 53.04 158.38 ± 42.76 0.014
*Values are mean ± SD.
p-values ¼ Between LVD and Non-LVD groups, Significant values are shown in bold.
NSTEMI¼Non-ST elevation myocardial infarction, STEMI¼ ST elevation myocardial infarction, AWMI ¼ anterior wall myocardial infarction,
IWMI¼ Inferior wall myocardial infarction, LVEF ¼ LV ejection fraction, LVEDD ¼ LV end diastole dimension, LVESD ¼ LV end systolic
dimension.
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healthy controls, CAD and LVD patients
The distribution of AT1 A1166C genotypes is shown in Table
2. The observed genotype frequencies of the studied poly-
morphism in healthy controls were in accordance with Har-
dyeWeinberg equilibrium (p > 0.05). Table 2 shows the risk of
CAD in relation to AT1 A1166C polymorphism. On comparing
the genotype frequency distribution in CAD patients with
that of healthy controls, no significant difference was
observed in the distribution of AT1 A1166C polymorphismsTable 2 e Analysis of AT1 A1166C gene polymorphisms in hea
Genotypes Controls (230) CAD (720) Non-LVD (491)
AA 165 (71.7) 553 (76.8) 400 (81.5)
AC 56 (24.3) 135 (18.8) 79 (16.1)
CC 9 (3.9) 32 (4.4) 12 (2.4)
AC þ CC 65 (28.2) 167 (23.2) 91 (18.5)
Significant values are shown in bold.
a p-value between healthy controls and CAD.
b p-value between Non-LVD and LVD.(AA vs AC; p-value ¼ 0.059, OR ¼ 0.71, AA vs CC; p-
value ¼ 0.927, OR ¼ 1.04, and AA vs AC þ CC; p-value ¼ 0.219,
OR ¼ 0.83; Table 2).
Further, we segregated CAD patients on the basis of
reduced (45%) and preserved (>45%) left ventricular ejection
fraction (LVEF) and compared with their status of AT1 A1166C
polymorphism. We found that higher percentage of CAD pa-
tients carryingAT1AC and CC genotypes had reduced ejection
fraction (45%) as compared to the patients with preserved
(>45%) ejection fraction. This frequency difference was sta-
tistically significant (AA vs AC; p-value ¼ 0.003, OR ¼ 1.81, AAlthy controls, CAD and LVD patients.
LVD (229) OR (95% CI) p-valuea OR (95% CI) p-valueb
153 (66.8) e e
56 (24.5) 0.71 (0.49e1.01) 0.059 1.81 (1.22e2.70) 0.003
20 (8.7) 1.04 (0.48e2.23) 0.927 4.33 (2.06e9.09) <0.001
76 (33.2) 0.83 (0.62e1.17) 0.219 2.19 (1.53e3.14) <0.001
Table 4 e Association of clinical characteristics of CAD






Patients 553 167 e
*Age at CAD diagnosis,
years
55.63 ± 9.09 56.16 ± 9.63 0.518
Male 485 (87.2) 143 (85.6) 0.280
Risk factors
Hypertension 240 (43.4) 77 (46.1) 0.298
Diabetes 177 (32.0) 53 (31.7) 0.514
Smoking 133 (24.1) 45 (26.9) 0.474
*BMI, kg/m2 24.33 ± 3.20 24.05 ± 2.43 0.586
Myocardial
Infarction (MI)




331 (59.9) 102 (61.1) e
Double vessel
disease (DVD)
93 (16.8) 32 (19.2) e
Triple vessel
disease (TVD)




45.30 ± 5.51 46.97 ± 6.33 0.031
LV end systolic
dimension, mm
30.85 ± 5.77 32.53 ± 6.52 0.038
LV posterior wall
thickness, mm
9.47 ± 1.23 9.50 ± 1.22 0.914
LV inter-ventricular
septum, mm
9.68 ± 1.35 9.63 ± 1.36 0.895
LV mass, gm 146.86 ± 46.21 149.77 ± 43.69 0.678
LV ejection fraction 50.45 ± 10.82 48.37 ± 12.20 0.035
Reduced LVEF (45%) 153 (27.7) 76 (45.5) <0.001
Significant values are shown in bold.
* Values are mean ± SD.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 1 4e2 2 1218vs CC; p-value <0.001, OR ¼ 4.33, and AA vs AC þ CC; p-value
<0.001, OR ¼ 2.19; Table 2).
We also looked for the association of AT1 A1166C poly-
morphism with LVD by changing the cut-off values for LVEF.
When CAD patients were categorized on the basis of different
subgroups of LVEF (below 31% to above 55%), the results
showed that the patients in lower LVEF subgroups had
significantly higher frequency of AT1 A1166C polymorphism
(p-value <0.001; Table 3).
3.3. AT1 A1166C polymorphism in CAD patients with
clinical characteristics
After evaluating association of AT1 A1166C polymorphism
with reduced LVEF, further analysis was extended to look for
the association of AT1 A1166C polymorphism with clinical
characteristics of CAD. The results showed that AT1 A1166C
polymorphism is significantly associated with reduced LVEF
(p-value <0.001), LVEF means (p-value ¼ 0.035) and other pa-
rameters of LV remodeling i.e. LV dimensions (LVEDD; p-
value ¼ 0.031, and LVESD; p-value ¼ 0.038; Table 4).
However when CAD patients were stratified on the basis of
risk factors like diabetes mellitus, hypertension and smoking
status, AT1 A1166C polymorphism did not modulate the risk
of CAD due to these factors.
3.4. Distributions for AT1 A1166C gene polymorphism
in STEMI subjects with preserved (LVEF >45%) and reduced
(LVEF 45%) left ventricular ejection fraction
In clinical practice it is well known fact that STEMI patients
are more prone to develop LVD. We observed that 70.2% of
LVD patients had previous STEMI. Therefore, we looked for
distribution of AT1 A1166C genotypes in STEMI patients with
preserved and reduced ejection fraction. Our results showed
that the subjects with AC and CC genotypes were more likely
to develop LVD as compared to wild type AA genotype (AA vs
AC; p-value ¼ 0.044, OR ¼ 1.79, AA vs CC; p-value ¼ 0.002,
OR ¼ 10.24; Table 5).
3.5. Multivariate analysis of AT1 A1166C
polymorphism in CAD patients with risk factors
Further, multivariate analysis was done to rule out the pos-
sibilities of development of LVD in CAD patients due to con-
founding factors such as smoking, diabetes, hypertension,
and STEMI (ST-elevation myocardial infarction). In multivar-
iate analysis we step-wise removed patients of one risk factor
at a time and did analysis of CAD patients with AT1 A1166C
polymorphism by excluding patients with known risk factors
of LVD such as smoking, diabetes, hypertension, and STEMITable 3 e Association of AT1 A1166C gene polymorphism with
fraction (LVEF).
Genotypes >55% n (%) 51e55 % n (%) 46e50 % n (%)
AA 180 (32.5) 112 (20.3) 105 (19.0)
AC þ CC 56 (33.5) 22 (13.2) 12 (7.2)
Significant value is shown in bold.(ST-elevationmyocardial infarction). In this analysiswe found
that non-smokers (p < 0.001), non-diabetic (p ¼ 0.003), non-
hypertensive (p ¼ 0.008), and their combination (p ¼ 0.013)
were at higher risk of developing LVD in CAD patients due to
AT1 A1166C polymorphism, while we did not find any signif-
icant association in case of excluding CAD patients with
STEMI (Table 6).4. Discussion
In the present study we explored the role of AT1 A1166C ge-
netic polymorphisms on left ventricular dysfunction in a
population of 720 angiographically confirmed CAD patients
who had already been on optimal treatment for this condition.
The main finding of the present study indicates that thedifferent subgroups based on left ventricular ejection
41e45 % n (%) 31e40 % n (%) <31% n (%) p-value
34 (6.1) 72 (13.0) 50 (9.0) e
23 (13.8) 33 (19.8) 21 (12.6) <0.001
Table 5 e Distributions for AT1 A1166C gene polymorphism in STEMI subjects with preserved (>45%) and reduced (≤45%)
left ventricular ejection fraction.
Genotypes >45% 45% p-value OR (95% CI)
AA 134 (83.2) 101 (67.3) e Reference
AC 25 (15.5) 34 (22.7) 0.044 1.79 (1.00e3.19)
CC 2 (1.2) 15 (10.0) 0.002 10.24 (2.28e45.99)
Significant values are shown in bold.
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 2 1 4e2 2 1 219individuals with AT1 1166 AC and CC genotypes (AA vs AC; p-
value ¼ 0.003, OR ¼ 1.81, AA vs CC; p-value <0.001, OR ¼ 4.33,
and AA vs AC þ CC; p-value <0.001, OR ¼ 2.19) are genetically
predisposed to LVD as compared to AA homozygote subjects.
In patients with cardiovascular disease, activity of the RAS
is often increased and contributes to a poor prognosis.22
Angiotensin II (Ang II), as active component of RAS, is an
acute vasoconstrictor that regulates systemic blood pressure
and vascular tone. Increased levels of Ang II have been sug-
gested to be involved in the pathophysiology of cardiovascular
disease.23 Physiologically AT1 receptors are the primary
mediator of Ang II.
Among several biallelic polymorphisms present in the AT1
receptor gene, A1166C transversion is particularly important,
located at 30 UTR. Although A1166C polymorphism does not
appear to be functional but tends to be a key geneticmarker or
in linkage disequilibrium with unidentified functional loci
which would affect the regulation of the gene. Earlier, a report
onmapping of 30 UTR SNPs onto a collection of experimentally
supported human miRNA targets, have confirmed that
A1166C polymorphism is located within the miRNA binding
sites and miR155 down-regulates the expression only of the
1166A, and not the 1166C allele of AT1 gene.24 In presence of
1166A allele, miRNA binds with target site and reduces the
expression of AT1 receptor gene while 1166C allele abolishes
the target site and impairs the ability of miR-155 binding,
thereby elevating the level of AT1 receptors. Also, it has been
suggested that after severe myocardial infarction (MI), the
level of AT1 receptors increases.25 Thus, increased AT1 re-
ceptor levels in 1166C allele carriers may lead higherTable 6 e Multivariate analysis between LVD and Non-LVD pa
Genotypes Non-LVD LVD
CAD patients without smoking
AA 320 (83.1) 100 (63.7)
AC þ CC 65 (16.9) 57 (36.3)
CAD patients without diabetes
AA 276 (80.5) 100 (68.0)
AC þ CC 67 (19.5) 47 (32.0)
CAD patients without hypertension
AA 220 (81.5) 93 (69.9)
AC þ CC 50 (18.5) 40 (30.1)
CAD patients without STEMI
AA 245 (79.8) 48 (70.6)
AC þ CC 62 (20.2) 20 (29.4)
CAD patients without smoking, diabetes, and hypertension
AA 130 (82.3) 43 (68.3)
AC þ CC 28 (17.7) 20 (31.7)
Significant values are shown in bold.probability of arteriolar vasoconstriction and increased blood
pressure followed by reduced cardiac output which may give
rise to LVD (Fig. 2).
The previous findings that co-relate AT1 receptor gene to
CAD and other cardiovascular diseases are contradicting.
Some studies support that the AT1 1166C allele is a predis-
posing genetic marker for CAD or MI8,26,27 but there other
reports contrary to these findings.28,29 In addition to CAD,
AT1 A1166C polymorphism has been also associated with
the severe form of essential hypertension,10,11 aortic stiff-
ness,7 and collagen type I synthesis, and myocardial stiff-
ness in patients with hypertensive heart disease12 and
cardiac hypertrophy in hypertrophic cardiomyopathy pa-
tients.13 Previously, AT1 1166C allele has also been associ-
ated with lower ejection fraction30 and increased left
ventricular mass.31 We had earlier reported an association
of AT1 A1166C polymorphism with LVD in a small cohort of
CAD patients.14
Analysis of association of AT1 A1166C polymorphism with
different subgroups based on left ventricular ejection fraction
(LVEF) shows a significant association of this polymorphism
with severe LVD as the patient in groups LVEF ¼ 31e40% and
below 31% were having significantly higher percentage of AC
and CC genotypes. Further, analysis of with clinical charac-
teristics shows that this polymorphism not only associated
with LVEF but also with other echocardiography parameters
such as LV end diastole dimension (LVEDD), and LV end sys-
tolic dimension (LVESD). These results strongly support our
hypothesis that AT1 1166C allele associated with LV
dysfunction. Further multivariate analysis results rule out thetients.
OR (95%CI) p-value FDR pcorr
Reference e e
2.86 (1.87e4.37) <0.001 0.044
Reference e e
1.96 (1.26e3.04) 0.003 0.040
Reference e e
1.93 (1.19e3.15) 0.008 0.040
Reference e e
1.62 (0.89e2.95) 0.111 e
Reference e e
2.42 (1.21e4.84) 0.013 0.040
Fig. 2 e Proposed model for molecular mechanism of association of AT1 1166C allele with LV dysfunction: AT1 1166C allele
in the 3′ UTR of AT1 gene abolishes miR-155 binding, which induces elevated levels of AT1 receptors that may lead to LV
dysfunction.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 1 4e2 2 1220possibilities of development of LVD in CAD patients due to
confounding factors such as smoking, diabetes, and hyper-
tension. The results confirm that AT1 A1166C polymorphism
may be responsible for development of LVD in CAD patients.
On analyzing other parameters of LV remodeling, the patients
with AT1 A1166C polymorphism had significantly higher LV
end systolic and diastolic dimensions, which indicates that
the patients with AC and CC genotypes were at higher risk of
developing LV remodeling.
As, in clinical practice, STEMI patients are more prone to
develop LVD. In line to this our data also showed that 70.2%
LVD patientswere having STEMI. Sowe looked forAT1A1166C
genotypes status in STEMI subjects. Also in STEMI subjects, a
significantly higher percentage of AC and CC genotypes were
found in LVD patients as compared to patients with preserved
LVD. These observations also indicate a close association of
AT1 1166C allele with the susceptibility of LVD.
LVD is a polygenic condition which may be influenced by
multiple genes other than AT1. We have previously shown the
association of NFKB1,32 MMP9,33 and MYBPC321 in genetic
predisposition of LVD. It may beworthwhile that further large,
well-designed association studies and screening of other
candidate gene polymorphisms is required to elucidate the
precise genetic susceptibility of the disease. Moreover, it willbe worthwhile to replicate the study in different populations
before any clinical implications.Conflicts of interest
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